Lentigen
Lentigen, operating as a division of Miltenyi Biotec under the Miltenyi Bioindustry brand, is a CDMO specializing in lentiviral vector manufacturing and engineered cell therapy production services for biotech companies, researchers, and large pharmaceutical organizations across 45+ countries.
- Company typePrivate
- Founded2005
- HeadquartersGaithersburg, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Lentigen does
Lentigen Corporation, founded in 2005 in Gaithersburg, Maryland, was originally engaged in the development and commercialization of gene delivery technologies for human diseases. The company has been integrated as a division of Miltenyi Biotec, a German-based life sciences company, and now operates under the Miltenyi Bioindustry CDMO brand. In this capacity, Lentigen/Miltenyi Bioindustry functions as a full-service Contract Development and Manufacturing Organization (CDMO) for cell and gene therapy products, specializing in lentiviral vector (LVV) manufacturing and engineered cell therapy production services.
The company's core technology platform comprises proprietary manufacturing and analytical systems including the CliniMACS Prodigy Platform (an automated closed-system cell therapy manufacturing platform), the CliniMACS Cell Factory, the MACSQuant Analyzer for cell analysis and quality control, and the Lentiviral Vector Platform supporting scalable production. Lentigen/Miltenyi Bioindustry offers specialized lentiviral vector products including VSV-G pseudotyped vectors for broad tropism applications, BaEV (Bicistronic Equatorial Vesiculovirus) pseudotyped vectors optimized for CAR NK cell manufacturing efficiency, and vectors designed specifically for in vivo gene therapy applications. The combined platform has manufactured over 900 GMP cell therapy batches, over 350 GMP lentiviral vector batches, and supported more than 100 clinical trials across 45+ countries, supported by 25 years of cumulative cell and gene therapy manufacturing experience.
The business model is centered on professional services CDMO revenue, generating income through custom contract manufacturing engagements spanning pre-clinical development through commercial-scale production. Pricing is quote-based and project-specific, with multi-year contract cadences. The company serves three primary customer segments: biotechnology companies developing novel cell and gene therapy products (primary), academic and research institutions seeking clinical translation support (primary), and large pharmaceutical companies requiring scalable commercial manufacturing (secondary). GTM motion is enterprise field sales with direct expert consultation, supplemented by industry events, webinars, case studies, and content marketing. The company has a strategic core partnership with CHA Biotech on the BaEV lentiviral vector platform for CAR NK manufacturing.
Lentigen firmographics
Firmographics- Name
- Lentigen
- Legal name
- Lentigen
- Website
- https://lentigen.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lentigen, operating as a division of Miltenyi Biotec under the Miltenyi Bioindustry brand, is a CDMO specializing in lentiviral vector manufacturing and engineered cell therapy production services for biotech companies, researchers, and large pharmaceutical organizations across 45+ countries.
- Ownership category
- akta.pro rank
Lentigen industry classification
Industry- Product category
- Cell and Gene Therapy CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where Lentigen is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lentigen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- CDMO Manufacturing Services: Contract development and manufacturing services for cell and gene therapy products, including lentiviral vectors and engineered cell therapies. Revenue generated through service contracts from pre-clinical through commercial scale manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CDMO service contracts |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Lentigen product offering
Product offeringCore offering
Lentigen operates as Miltenyi Bioindustry, a full-service contract development and manufacturing organization (CDMO) for cell and gene therapy products. The company provides engineered T cell and NK cell manufacturing, lentiviral vector services including VSV-G, BaEV, and in vivo gene therapy vectors, and global quality and regulatory support from pre-IND through market approval across more than 45 countries.
Product overview
Miltenyi Bioindustry is a full-service CDMO (Contract Development and Manufacturing Organization) for cell and gene therapy products, operating as a division of Miltenyi Biotec. The company offers a platform-plus-services architecture consisting of proprietary manufacturing and analysis platforms (CliniMACS Prodigy Platform, MACSQuant Analyzer, CliniMACS Cell Factory, Lentiviral Vector Platform) combined with comprehensive CDMO services spanning engineered T cell and NK cell manufacturing, lentiviral vector services (VSV-G, BaEV, and in vivo gene therapy vectors), and global quality and regulatory support. The company leverages 25 years of experience and has manufactured over 900 GMP cell therapy batches and 350 GMP lentiviral vector batches supporting over 100 clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- Lentigen: Lentiviral vector platform and services brand under Miltenyi Bioindustry, offering VSV-G lentiviral vectors, BaEV lentiviral vectors, and lentiviral vectors for in vivo gene therapies.
Products and services
- Engineered T cell manufacturing CDMO manufacturing services for engineered T cell therapies, part of the cell and gene therapy service offering for biotech companies, researchers, and large pharmaceutical clients.
- Engineered NK cell manufacturing CDMO manufacturing services for engineered NK cell therapies, including CAR NK manufacturing enhanced by BaEV lentiviral vector technology, offered as part of the cell and gene therapy CDMO portfolio.
- VSV-G lentiviral vectors Lentiviral vector services utilizing the VSV-G envelope for broad tropism and stable gene expression in various cell types, used in gene therapy manufacturing for biotech and pharma clients.
- BaEV lentiviral vectors Lentiviral vector services using Baboon envelope (BaEV) pseudotyping to enhance CAR NK cell manufacturing efficiency, developed in collaboration with CHA Biotech.
- Lentiviral vectors for in vivo gene therapies Lentiviral vector services specifically designed for in vivo gene therapy applications, supporting clients developing directly administered gene therapies.
- Quality and regulatory support Global quality and regulatory support services from pre-IND through market approval, with documentation and submission experience spanning over 45 countries for cell and gene therapy clients.
Quantifiable outcome
- 900+ GMP cell therapy batches manufactured
- +3 more outcomes
Companies that use Lentigen
Customer profileSegments3 records
Ideal customer profiles3 records
Lentigen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Lentigen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CHA BiotechcoreMiltenyi Biotec and CHA Biotech have collaborated on the BaEV (Bicistronic Equatorial Vesiculovirus) lentiviral vector platform to enhance CAR NK (Chimeric Antigen Receptor Natural Killer) cell manufacturing efficiency. This collaboration leverages CHA Biotech's expertise in cell therapy development and Miltenyi's proprietary BaEV pseudotyping technology to improve the scalability and productivity of CAR NK manufacturing processes.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Lentigen competitors and assessment
Company assessmentBroad incumbents
- WuXi Advanced Therapies (WuXi AppTec):
- Lonza Group: Global CDMO with one of the largest cell and gene therapy manufacturing footprints, offering viral vector and cell therapy services comparable to Lentigen's scope but at significantly greater scale and across multiple modalities.
- Catalent (Novo Holdings): Major CDMO with cell therapy and viral vector manufacturing services competing directly with Lentigen for biotech CDMO contracts, with broader service lines and larger commercial-scale capacity.
- Thermo Fisher Scientific (Pharma Services / Brammer Bio): Through its Brammer Bio viral vector CDMO and broader pharma services, Thermo Fisher competes with Lentigen in lentiviral vector and cell therapy manufacturing for biotech and large pharma clients.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Lentigen social profiles
Digital presenceLentigen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lentigen leadership team
Management profileNumber of profiles
Lentigen funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lentigen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lentigen
What does Lentigen do?
Lentigen operates as Miltenyi Bioindustry, a full-service contract development and manufacturing organization (CDMO) for cell and gene therapy products. The company provides engineered T cell and NK cell manufacturing, lentiviral vector services including VSV-G, BaEV, and in vivo gene therapy vectors, and global quality and regulatory support from pre-IND through market approval across more than 45 countries.
Is Lentigen a public or private company?
Lentigen is a private company. It is classified as corporate owned and is currently operating.
When was Lentigen founded?
Lentigen was founded in 2005. It employs 11 to 50 people.
Where is Lentigen based?
Lentigen is headquartered in Gaithersburg, United States, in the North America region.
How does Lentigen make money?
One revenue line is on record: CDMO Manufacturing Services.
Who are Lentigen's main competitors?
Broad incumbents on record are WuXi Advanced Therapies (WuXi AppTec), Lonza Group, Catalent (Novo Holdings) and Thermo Fisher Scientific (Pharma Services / Brammer Bio).
Does Lentigen have an API?
No public API is recorded for Lentigen.
What industry is Lentigen in?
Lentigen's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.